Performance of the Travoprost Intraocular Implant: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Performance of the Travoprost Intraocular Implant (NCT06582732), a non-randomized phase 2 study. The primary outcome is Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 12 Months Post-administration.

2. Clinical Question

The study is registered as a Phase 2 investigation of implant performance. Its primary endpoint is a laboratory measurement in study eyes, assessed by liquid chromatography tandem mass spectrometry. The registry summary also describes determining residual drug in implants after explantation and measuring aqueous humor concentrations at specified timepoints through 24 months.

The cohorts are distinguished by the time at which the implant is exchanged: Month 3, Month 6, Month 12, Month 15, Month 18, Month 21, or Month 24. Those timings define the study groups, but they do not by themselves create a randomized comparison. Because allocation is non-randomized and masking is absent, differences between groups could reflect factors other than the exchange schedule. The record does not report a controlled comparison designed to isolate the effect of one exchange time from another.

The clinical question is therefore primarily descriptive: what drug concentrations and residual drug amounts were observed at the specified times? The posted record does not include the measured primary endpoint value, its variability, or an inferential comparison. It consequently does not allow a reader to assess the magnitude or precision of the reported concentration result from the registry information alone.

3. Trial Design

This is a prospective, non-randomized, open-label, single-center Phase 2 study. The registry lists an enrollment of 210 and a sequential study model. The study start date is 2021-03-10, the primary completion date is 2023-11-02, and the status is completed. Glaukos Corporation is listed as the sponsor.

Participants were assigned to cohorts described by the planned implant exchange time. The seven cohort labels correspond to exchange at Month 3, Month 6, Month 12, Month 15, Month 18, Month 21, or Month 24. The intervention descriptions likewise refer to a travoprost intracameral implant exchanged at those times. The record does not describe a separate untreated or active-comparator arm. The cohorts should therefore be understood as groups within a non-randomized study, not as randomized treatment and control groups.

Open-label means masking was not used, according to the registry. Prospective indicates that the study was registered as following participants forward for assessment; the registry record does not provide further detail about visit procedures or operational conduct. The record identifies the primary endpoint population as study eyes, but does not explain how eyes were selected or whether all eligible eyes contributed measurements.

The stated objective is to assess implant performance by measuring residual travoprost in explanted implants and aqueous humor concentrations of travoprost free acid at specified timepoints through 24 months. The primary outcome specifically concerns aqueous humor concentration at 12 months. Secondary outcomes concern the percent of residual travoprost in explanted implants at the listed exchange timepoints.

Although the registry marks the study completed, completion status is not a substitute for posted results. The record lists 14 outcome measures and 0 analyses, and it does not report the primary endpoint estimate, group-level outcome summaries, or a statistical comparison. The protocol details, allocation process, and rationale for the cohort sequence are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Only the first 6 of 7 groups are shown.

Initial Study Period

Reasons for not completing this period:

Post-exchange Study Period

Analysis population for the primary outcome, as defined in the registry: study eyes

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: only a single eye (defined as the study eye) was analyzed in the study

Only the first 6 of 8 groups are shown.

6. Primary Endpoint

The registry lists the primary outcome as Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 12 Months Post-administration, measured over month 12.

The primary endpoint is the concentration of travoprost free acid in aqueous humor, measured in ng/mL at 12 months after administration. The registry specifies a mean as the summary measure and a standard deviation as the measure of dispersion. The assay is identified as liquid chromatography tandem mass spectrometry, and the stated population is study eyes.

This endpoint is used to characterize drug exposure in the fluid of the eye at a specified follow-up time. A concentration measurement provides a laboratory-based description of the amount of the specified drug form detected at that timepoint. The mean describes the central value across the measured observations, while the standard deviation describes how spread out those observations are around the mean. These summaries answer different questions: a mean alone does not show how variable measurements were across study eyes.

As a general statistical point, a concentration endpoint is not itself a direct measure of clinical benefit or harm. Its interpretation depends on the clinical context and on how the measurement relates to outcomes that matter to patients. The registry identifies the endpoint and assay but does not report the observed mean, standard deviation, confidence interval, or individual-level distribution. The concentration result and its precision therefore cannot be evaluated from the registry record.

The endpoint also represents a particular measurement time, not a complete description of exposure over the whole follow-up period. The broader study objective includes measurements at specified timepoints through 24 months and residual drug in explanted implants, but those additional aims do not replace the stated primary endpoint.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry identifies a continuous primary outcome summarized by a mean and standard deviation. It also records 0 analyses. No primary endpoint estimate, confidence interval, hypothesis test, or model result is reported in the registry record. The explanations below describe general statistical concepts; they are not claims about methods that this study used unless the registry explicitly identifies them.

What does a mean concentration describe?

In general, the mean is the arithmetic average of observed measurements. For a concentration outcome, it summarizes the central level of the measurements on the original scale. It can be useful when the scientific question concerns average concentration across the measured study eyes. However, the mean does not show whether measurements cluster closely together or vary widely. It can also be influenced by unusually high or low observations.

The standard deviation describes the spread of individual measurements around the mean. It is not the uncertainty of the mean. A confidence interval for the mean would address uncertainty in estimating the underlying average, using both the observed variability and the amount of information available. The registry specifies mean and standard deviation as the primary summary, but a confidence interval is not reported in the registry record. Without the observed values and their uncertainty, readers cannot assess how precise the primary estimate would be.

Why does the assay matter?

The endpoint is measured using liquid chromatography tandem mass spectrometry. In general, the measurement method is part of the definition of a laboratory endpoint: it specifies how the target substance is detected and quantified. Interpretation can depend on assay performance, sample handling, timing, and other measurement procedures. The registry names the assay but does not report validation characteristics, quality-control procedures, limits of detection or quantification, or handling details. These details are not reported in the registry record and should not be assumed.

The outcome is a concentration at a particular follow-up time. In general, a single-timepoint measurement describes the value at that time, rather than the entire concentration trajectory. Measurements across multiple timepoints can describe how concentrations vary over follow-up, but the registry does not report the actual concentration results at the specified timepoints.

How should cohort comparisons be understood?

General statistical interpretation of non-randomized cohorts requires caution. Randomization, when used, is intended to balance measured and unmeasured characteristics on average. Here, the registry states that allocation was non-randomized. Consequently, comparisons across exchange-time cohorts may be affected by baseline differences, clinical decisions, follow-up patterns, or other factors. The record does not describe a randomization procedure, covariate adjustment, or a causal analysis plan.

The sequential model and cohort-specific exchange schedules are recorded design features. They do not establish that cohort outcomes are directly comparable. A valid comparison would require a clearly defined question, suitable handling of differences between groups, and uncertainty estimates. The registry does not report such an analysis. No comparison should be constructed from the cohort labels alone.

What do planning calculations mean?

General sample-size illustrations are planning exercises, not observed results and not evidence of the study's achieved power. The stated assumptions for planning illustrations are a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the effect to detect expressed as a fraction of the observed effect. Those assumptions describe a hypothetical calculation framework; they do not establish that the trial itself was designed using that framework. The registry does not report the trial's sample-size justification or the effect used for any such calculation. An illustration based on an observed effect should not be described as observed power.

The registry lists an enrollment of 210, but enrollment alone does not reveal the number of evaluable observations for the primary endpoint. The record does not report endpoint-specific denominators, exclusions, missing measurements, or the extent of follow-up for each outcome. It is therefore not possible to infer precision from enrollment alone.

Why does over-dispersion matter?

General explanation: over-dispersion occurs when observed variability is greater than a statistical model assumes. If a model understates variability, standard errors can be too small and confidence intervals too narrow, making evidence appear more precise than it is. Appropriate methods depend on the outcome type and model. The primary endpoint is continuous, but the registry does not report a model or variance adjustment. There is no basis in the registry record for saying that over-dispersion was assessed or that any particular approach was used.

For the same reason, statistical significance and clinical importance should not be treated as interchangeable concepts. A statistical test concerns compatibility with a specified model and null hypothesis, while clinical interpretation requires context about what the measured concentration means. Neither a test result nor a clinical threshold is reported for the primary endpoint in the registry record.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("Cohort 1 (12-month Exchange)")
n   <- c(29)
m   <- c(5.57)
sp  <- c(3.02)
sd  <- sp      # posted standard deviations
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  Cohort 1 (12-month Exchange)  29  5.570  3.020  4.421  6.719

11. Multiplicity, Missing Data and Analysis Populations

The registry lists 14 outcome measures, including the primary aqueous humor concentration endpoint and secondary residual-travoprost measures at several exchange timepoints. When many outcomes or timepoints are examined, general statistical practice recognizes a multiplicity issue: the chance of at least one apparently notable result can increase if many tests are performed without an appropriate strategy. The registry record does not report whether multiplicity was addressed, whether outcomes were hierarchically tested, or whether any adjustments were planned.

Missing-data handling is not reported in the registry record. The record does not state how missing concentration measurements, unavailable explanted implants, withdrawals, or incomplete follow-up were handled. It also does not provide outcome-specific denominators or explain whether analyses used all enrolled participants, a subset, or another defined population. The primary endpoint names study eyes as its population, but further analysis-population details are not reported.

The registry lists 0 analyses, so there are no posted statistical results from which to assess the analysis population, exclusions, missingness, or multiplicity procedures. These gaps limit assessment of both potential bias and the precision of any estimate. In general, missingness can affect results when the reason for unavailable observations is related to the outcome or to participant characteristics. The pattern and handling of missing data would be needed to evaluate that possibility.

The record also does not report an analysis plan, interim analyses, or sample-size justification. Their presence or absence beyond what is recorded should not be inferred. The registered outcome list is not enough to determine which comparisons were prespecified or how confirmatory conclusions were intended to be drawn.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: myocardial infarction (3.3%).

The registry reports adverse-event counts by cohort. For serious adverse events, the record lists 30 at risk in each cohort; affected counts are 1 in Cohort 1 (12-month Exchange), 0 in Cohort 2 (3-month Exchange), 0 in Cohort 3 (6-month Exchange), 0 in Cohort 4 (24-month Exchange), 1 in Cohort 5 (21-month Exchange), 0 in Cohort 6 (18-month Exchange), and 0 in Cohort 7 (15-month Exchange). The record lists deaths as 1 in Cohort 1 and 1 in Cohort 5, with 0 in the other cohorts.

For other adverse events, the listed affected counts are 4 in Cohort 1, 0 in Cohort 2, 5 in Cohort 3, 3 in Cohort 4, 0 in Cohort 5, 1 in Cohort 6, and 1 in Cohort 7. Myocardial infarction is listed among the top serious terms at 3.3%. The registry does not identify a causal relationship between these events and the implant in the information.

These counts are descriptive, not a randomized safety comparison. The record does not provide event timing, exposure-adjusted rates, severity details beyond the serious-event classification, or an adjudication method. A count of affected participants is also distinct from a count of event episodes. Because the study is non-randomized and the registry does not report an analytical comparison, the listed figures should not be read as evidence that one exchange schedule caused more or fewer events.

13. What the Result Does, and Does Not, Mean

The registry record establishes that a prospective, non-randomized, open-label, single-center study was conducted to evaluate the travoprost intracameral implant. It identifies the primary measurement as mean travoprost free acid concentration in aqueous humor at 12 months and describes secondary measurements of residual travoprost in explanted implants. It also provides cohort definitions, study status, enrollment, and adverse-event counts.

It does not report the primary concentration estimate or its variability. Without those values, the posted record cannot show the observed concentration level or how much measurements varied across study eyes. It does not report a confidence interval, statistical test, or model result for the primary outcome. Although the study is marked completed, completion status alone does not establish what the measured results were.

The record also does not establish whether the implant achieves a particular clinical objective. A laboratory concentration is a measure of drug exposure, not by itself a patient-centered outcome or proof of clinical benefit. The registry provides no threshold for interpreting a concentration and no reported clinical comparison that would connect the measured concentration to a treatment effect.

Similarly, the adverse-event entries describe counts but do not establish causation. There is no randomized comparator, and the record does not provide an adjusted safety analysis. The counts should therefore be read as events recorded by cohort, not as estimates of comparative risk attributable to the implant or exchange timing.

For statistical interpretation, the main limitation is absence of posted outcome analyses. The registry lists 14 outcome measures and 0 analyses. As a result, the record supports a description of what the study set out to measure and how it was organized, but not a conclusion about the magnitude, precision, or clinical meaning of its primary result. Those conclusions would require outcome values and analysis details that are not reported in the registry record.

14. Why This Trial Matters Statistically

This study is statistically notable because it focuses on laboratory measures of implant performance rather than reporting a randomized comparison of clinical outcomes. Its primary endpoint is a continuous concentration measure, summarized by a mean and standard deviation, while secondary outcomes describe residual drug in explanted implants. Those endpoints can characterize drug exposure and remaining drug at specified times, but their interpretation depends on the actual measurements and their uncertainty.

The cohort structure makes design-aware interpretation important. The exchange schedules range from Month 3 to Month 24, but allocation is non-randomized and the study is open-label. A difference across cohorts could reflect the exchange schedule, differences in the participants or study eyes assigned to each cohort, or other factors. Without a reported comparative analysis and supporting methods, the cohort labels alone do not support a causal conclusion.

The record also illustrates the distinction between a completed study and a complete statistical report. Although the status is completed and enrollment is listed, the primary endpoint value and statistical analyses are not reported in the registry record. This limits assessment of precision, missing data, multiplicity, and the relation between laboratory measurements and clinical outcomes.

For clinical researchers, the record underscores the value of reporting endpoint estimates alongside measures of uncertainty, analysis populations, missing-data handling, and clearly defined comparisons. These elements help readers distinguish a descriptive measurement from evidence about differences between groups. In their absence, the design and registered objectives can be described, but the strength and meaning of the study's outcome evidence remain undetermined from the registry record.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations are specific to the design and reporting of this study. The allocation is non-randomized, so the cohorts may differ in ways that affect measured concentrations, residual drug, or adverse events. The study is open-label, and the registry does not describe masking of outcome assessment. It is also single-center, which may limit how well findings would generalize to other settings, although the registry does not provide information to quantify that concern.

The cohorts are defined by different implant exchange times rather than by a stated randomized control comparison. Thus, any apparent difference between cohort results would require careful interpretation and could not automatically be attributed to exchange timing. The registry record does not report an adjustment strategy, a comparative estimand, or a protocol rationale for the sequence of exchange schedules.

The primary endpoint is a laboratory concentration at 12 months. A single timepoint does not characterize the complete concentration profile, and the registry does not provide the measured result or supporting uncertainty. Although the broader objective includes measurements through 24 months and residual drug in explanted implants, numerical results for these outcomes are not reported in the registry record.

Reporting is incomplete for statistical appraisal: the record lists 14 outcome measures and 0 analyses. The sample-size justification, interim analyses, analysis populations, missing-data procedures, multiplicity approach, assay validation details, and any covariate adjustment are not reported in the registry record. The listed enrollment does not reveal endpoint-specific completeness. Adverse-event counts lack reported causal assessment and comparative analysis. Together, these limitations mean that the registry information is insufficient to judge the precision or clinical implications of the study outcomes.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Performance of the Travoprost Intraocular Implant — NCT06582732.
• Registry record last updated 2024-10-15; status last verified 2024-09.
• Results first posted 2024-10-15.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT06582732 is a completed Phase 2, prospective, non-randomized, open-label, single-center study sponsored by Glaukos Corporation. The registry lists an enrollment of 210 and a sequential model. The study start date is 2021-03-10, and the primary completion date is 2023-11-02.

The study evaluates a travoprost intracameral implant in study eyes associated with open-angle glaucoma or ocular hypertension. Cohorts are defined by implant exchange at Month 3, Month 6, Month 12, Month 15, Month 18, Month 21, or Month 24. The primary endpoint is mean aqueous humor travoprost free acid concentration at 12 months, measured by liquid chromatography tandem mass spectrometry. Secondary outcomes address percent residual travoprost in explanted implants.

The registry lists 14 outcome measures and 0 analyses. It does not report the primary endpoint result or its precision. Adverse-event counts are listed by cohort, but the record does not establish causation or provide a comparative safety analysis. The posted information supports description of the trial design and registered outcomes, not conclusions about treatment effects.